Navigation Links
Statins may treat blood vessel disorder that can lead to fatal strokes
Date:1/26/2009

SALT LAKE CITY In a finding that could save thousands of lives a year, University of Utah School of Medicine researchers have shown that a blood vessel disorder leading to unpredictable, sometimes fatal, hemorrhagic strokes, seizures, paralysis or other problems is treatable with the same statin drugs that millions of people take to control high cholesterol.

If the results of a study in mice are confirmed in a pilot trial with people, statins could provide a safe, inexpensive treatment for cerebral cavernous malformation (CCM), a disorder with no known drug therapy, according to U of U cardiologist Dean Y. Li, M.D., Ph.D., director of the Molecular Medicine Program and corresponding author of a study published Jan. 18 in Nature Medicine online.

"Brain surgery or radiation treatment has been the only option for CCM patients. But because of the risks in those operations, neurosurgeons are reluctant to perform them unless the patient is in immediate danger," Li said. "Our study proposes a potential strategy for a simple drug therapy that could cost only a few dollars a month at a pharmacy. However, our animal studies must first be evaluated in a pilot clinical trial being initiated."

Kevin J. Whitehead, M.D., also a cardiologist, assistant professor of internal medicine, and first author of the study, now is recruiting 50 to 100 people diagnosed with CCM to join a pilot trial of statins.

CCM is a disorder in which blood vessels in the brain become dilated and weakened, and leak blood, causing strokes, headaches, seizures or other problems. Diagnosing CCM can be problematic. Some people are diagnosed after experiencing symptoms and undergoing an MRI; others find out they have CCM during an MRI for an unrelated problem. An estimated 25 percent of people with CCM experience no symptoms and never know they have it. In worst-case scenarios, "people don't know they have CCMs until they suffer from an acute brain attack," Li
'/>"/>

Contact: Phil Sahm
phil.sahm@hsc.utah.edu
801-581-2517
University of Utah Health Sciences
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Statins may prevent miscarriages
2. Studies point to novel target for treating arrhythmias
3. Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment
4. World breakthrough in treating premature babies
5. Research shows cells inactive state is critical for effectiveness of cancer treatment
6. The quest for specific anti-inflammatory treatment
7. Promising new drug being evaluated as possible treatment option for fragile X syndrome
8. UC Davis discovery offers hope for treating kidney cancer
9. Miscarriage and infertility treatment increase pre-eclampsia risk
10. UC Davis team refines cancer treatments to reduce potential nerve damage
11. In just 5 years, gene discovery to clinical trial of potential treatment

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ning new doors to understanding how sounds associa...marine mammal or if they hear it at all. , The ... that NASA uses to detect flaws in the space shutt...cientists to peek inside the giant head of a whale...al replicas of a whale,s hearing anatomy using a b...
(Date:11/24/2009)...ican College of Medical Toxicology (ACMT) have sig... of the Journal of Medical Toxicology (JMT), the...2010. It was previously published by the Universi...ical Toxicology , an international, peer-reviewed ... practice of medical toxicology. The quarterly jo...
(Date:11/24/2009)...ber 24, 2009) New research on bacterial communiti...veals predictable temporal patterns, suggesting th...rs for monitoring climate change in the polar regi...dings of the National Academy of Sciences Early E...x rivers shifted synchronously over time, correlat...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Sigma Aldrich Elects George M Church as Director 14337 1Sigma Aldrich Elects George M Church as Director 14337 2ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results 5193 1Case Western Reserve University discovers Merkel cell originates from skin not the neural crest 10243 1Case Western Reserve University discovers Merkel cell originates from skin not the neural crest 10243 2
...homa County,s Use of PocketCop on BlackBerry Smart...rmed and In Touch, WALL, N.J., Nov. 20 BIO-key I...ader in finger-based biometric,identification and ...elevised report on the Oklahoma County Sheriff,s O... ABC affiliate in Oklahoma City. The,November 18th...
...hinas CO 2 emissions from using coal are set to d...n the context of mitigating global climate change....energy system, it is vital to minimise emissions w...vey (BGS) attended the launch of the Near Zero Emi... today. The aim of this study is to look at the fe...
...PITTSBURGH Carnegie Mellon University graduate eng...Lima de Azevedo, Benjamin Flath and Constantine Sa...competition called Tomorrows Energy Ambassadors, M...e contest, sponsored by Johnson Controls Inc., ask...rtant energy and sustainability issues in a letter...
Other Biology News:BIO-key(R) PocketCop(R) Project 'Leading the Nation' According to Televised Report 2UK scientists lead China closer to carbon capture and storage 2Carnegie Mellon students win contest 2Carnegie Mellon students win contest 3
(Date:11/24/2009)...ovember24/PRNewswire-FirstCall/--deCODE,genetics,I...oticefrom,theNasdaqStockMarketthattradinginthecomp...9andaForm25-NSEwillbefiledwiththe,SecuritiesandExc...,fromlistingonNasdaq,unlessthecompanyfilesanappeal...asfiledsuchanappeal,which,willstaythesuspensionand...
(Date:11/24/2009)....24/PRNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: ...gandcommercializingnovelpainmanagementtherapies,an...ecutiveOfficer,isscheduledtopresentatthe21stAnnual...-2,2009atTheNewYorkPalaceHotelinNewYork,NewYork. ,...fficer,willbeavailabletorespondtoquestionsduringth...
(Date:11/24/2009)..., TORONTO,Nov.24/PRNewswire-FirstCall/-HamiltonTh...adingproviderofadvancedlasersystemsandinstrumentsf...ayreportedoperationalandfinancialresultsforthethir...s,-Revenuewas$1.46millioncomparedwith$1.43million...ith66.1percentinQ3,2008,-Netlossreducedto$148,000c...
(Date:11/24/2009)...rogram Connects Customers with Partners Validated ...Genotek Products , Ottawa... leading provider of products for biological sampl... announced its new global partner program. The pro...ek,s partner community and is designed to help par...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
..., , High ... RT-PCR and microarray gene expression analysis...tion in , minutes: no grinding ...nt reagents protect and preserve , ... Faster and easier multi-sample , ...
...f siRNA applications, including , ...delivery of , hundreds to thous... studies describe performing trans...l formats. Ambion has developed two reagents, siPO... and siPORT siRNA , Electropora...
...tion efficiency and low cell , ...sful gene , silencing experimen... choosing the right transfection agent an...evels of transfection efficiency can be achieved ,...tocol is optimized for a , part...
Other Biology Technology:Hands-free Tissue Disruption No Homogenization Needed 2Hands-free Tissue Disruption No Homogenization Needed 3Hands-free Tissue Disruption No Homogenization Needed 4Hands-free Tissue Disruption No Homogenization Needed 5Hands-free Tissue Disruption No Homogenization Needed 6Hands-free Tissue Disruption No Homogenization Needed 7High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 2High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 3High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 4High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 5High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 6High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 7High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 8High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 9High Throughput siRNA Delivery In Vitro: From Cell Lines to Primary Cells 10Optimizing siRNA Transfection for RNAi 2Optimizing siRNA Transfection for RNAi 3Optimizing siRNA Transfection for RNAi 4Optimizing siRNA Transfection for RNAi 5Optimizing siRNA Transfection for RNAi 6Optimizing siRNA Transfection for RNAi 7Optimizing siRNA Transfection for RNAi 8Optimizing siRNA Transfection for RNAi 9Optimizing siRNA Transfection for RNAi 10Optimizing siRNA Transfection for RNAi 11
...exchange media are rigid macroporous hydrophilic m...tes at moderate pressures, while the macroporous b...hilic matrix reduces nonspecific binding. Macro-Pr...exchanger with very high flow rates and resolution...
Rat siTrio from B-Bridge International
Mouse Anti-Aggrecan xxPEN Monoclonal Antibody, Unconjugated, Clone BC-4 from Abcam
Rabbit Anti-L Kynurenine Polyclonal Antibody, Unconjugated from Abcam
Biology Products: